Enliven Therapeutics (ELVN) closed at $46.41 on November 19, 2026, up 3.4% from the previous close, on volume of 715,804 shares (30-day average 1,396,203).
Data as of November 19, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 28, 2026 | Calendar Call Spread | 18-Dec-26 : 15-Jan-27 45 C | 200 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 18, 2026. See the largest for 5, 30, 60 and 90 days
Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update
PRNewswire (Thu, 5-Nov 4:05 PM ET)
PRNewswire (Wed, 14-Oct 4:30 PM ET)
ELVN Gains a Clear FDA Path for a 450-Patient Phase 3 Relcobatinib Study in Previously Treated CML
Market Chameleon (Wed, 7-Oct 7:04 AM ET)
PRNewswire (Tue, 6-Oct 4:06 PM ET)
Enliven Therapeutics to Present at Upcoming Investor Conferences
PRNewswire (Thu, 3-Sep 4:05 PM ET)
PRNewswire (Mon, 31-Aug 6:06 PM ET)
ELVN-001 Shows Promising Phase 1 Results, FDA Alignment Paves Way for Phase 3 ENABLE-2 Trial
Market Chameleon (Thu, 11-Jun 6:32 AM ET)
Market Chameleon (Fri, 9-Jan 6:14 AM ET)
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Enliven Therapeutics trades on the NASDAQ stock market under the symbol ELVN.
As of November 19, 2026, ELVN stock price climbed to $46.41 with 715,804 million shares trading.
ELVN has a beta of 0.53, meaning it tends to be less sensitive to market movements. ELVN has a correlation of 0.01 to the broad based SPY ETF.
ELVN has a market cap of $3.32 billion. This is considered a Mid Cap stock.
In the last 3 years, ELVN traded as high as $62.32 and as low as $9.80.
The top ETF exchange traded funds that ELVN belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
ELVN has outperformed the market in the last year with a price return of +105.4% while the SPY ETF gained +9.6%. However, in the short term, ELVN had mixed performance relative to the market. It has underperformed in the last 3 months, returning -22.7% vs -6.5% return in SPY. But in the last 2 weeks, ELVN shares have fared better than the market returning -1.8% compared to SPY -6.6%.
ELVN support price is $43.50 and resistance is $46.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELVN shares will trade within this expected range on the day.